The effectiveness of digital health interventions for type 2 diabetes in underserved populations: A systematic review and meta-analysis.

Prim Care DiabetesAug 17, 2026 (epub)
Clinical ResearchEndocrinology

Naseem Eisa, Omar Barood

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the impact of digital health interventions (DHIs) on glycemic control in underserved adults with type 2 diabetes across 12 randomized controlled trials involving 1835 participants. The analysis revealed a statistically significant reduction in hemoglobin A1c (HbA1c) by 0.37 percentage points compared to control, indicating DHIs can improve diabetes management in these populations.

Key findings

  • Digital health interventions led to a mean HbA1c reduction of -0.37 percentage points.
  • The analysis included 12 randomized controlled trials with a total of 1835 participants.
  • Moderate-to-substantial heterogeneity was observed (I² = 69.9%).
  • Overall certainty for HbA1c outcomes was rated as moderate.

Why it matters

Improving glycemic control in underserved populations is crucial for reducing health disparities in diabetes management. Digital health interventions may offer a viable solution to enhance access and support for these patients.

Source

PubMed · PMID 42608227

Published in Prim Care Diabetes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.